0001209191-20-022241.txt : 20200401 0001209191-20-022241.hdr.sgml : 20200401 20200401181942 ACCESSION NUMBER: 0001209191-20-022241 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200330 FILED AS OF DATE: 20200401 DATE AS OF CHANGE: 20200401 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Krognes Steve E. CENTRAL INDEX KEY: 0001666236 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 20766794 MAIL ADDRESS: STREET 1: 863 MITTEN ROAD, SUITE 102 CITY: BURLINGAME STATE: CA ZIP: 94010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Denali Therapeutics Inc. CENTRAL INDEX KEY: 0001714899 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463872213 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 866-8548 MAIL ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-30 0 0001714899 Denali Therapeutics Inc. DNLI 0001666236 Krognes Steve E. C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 CFO and Treasurer Common Stock 2020-03-30 4 S 0 1428 19.48 D 1006488 D Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.46 to $19.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. /s/ Tyler Nielsen, by power of attorney 2020-04-01